Breaking News, Collaborations & Alliances

Autifony, Jazz Partner on Ion Channel Targets for Neurological Disorders

Autifony will lead drug discovery and preclinical development, Jazz will lead clinical development, mfg., regulatory activities, and commercialization.

Autifony Therapeutics, a company involved in the development of pharmaceuticals for rare CNS disorders and other serious brain diseases, has entered into an exclusive global licensing agreement with Jazz Pharmaceuticals plc, for up to $770.5 million to discover and develop drug candidates targeting two different ion channel targets associated with neurological disorders. Autifony will lead drug discovery and preclinical development activities on the two targets. Subsequent to successful compl...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters